Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo

Medicare Coverage of GLP-1 Drugs (CRS Report for Congress)

Premium   Purchase PDF for $24.95 (3 pages)
add to cart or subscribe for unlimited access
Release Date Sept. 9, 2024
Report Number IF12758
Report Type In Focus
Authors Laura A. Wreschnig
Source Agency Congressional Research Service
Summary:

Glucagon-like peptide-1 (GLP-1) receptor agonists, marketed under brand names such as Wegovy and Ozempic, are a class of medications used primarily in the treatment of type 2 diabetes mellitus (T2DM). Recently, GLP-1 drugs have gained attention for their effectiveness in obesity treatment. Given the increasing prevalence of obesity amongst Medicare beneficiaries, the demand for GLP-1 drugs also has increased, leading to discussions about their coverage under Medicare’s outpatient prescription drug benefit (Part D), the associated spending implications, and policy considerations for Congress. This In Focus provides a brief overview of GLP-1 drugs, their current coverage status under Medicare Part D, and related policy considerations.